BIOFARM
96 articole · RSS
Biofarm Ends H1/2026 With 46% Lower Net Profit, 15% Lower Sales Income
Drug and supplement producer Biofarm (stock symbol: BIO), which was recently acquired by Polish group Polpharma for RON1.3 billion, had a net profit of RON26.4 million in January-June 2026, down 46% year-over-year, as per the company's half-yearly financial re...
PwC Romania Assisted Polish Group Polpharma in Acquiring Romania’s Biofarm
PwC Romania provided financial and tax due diligence services, as well as transaction support services, to the Polish pharmaceutical group Polpharma in connection with its acquisition of Bio...
Polpharm Plans To Continue Investments In Development Of Biofarm After Takeover
Polish pharmaceutical group Polpharma, which has recently acquired the Romanian drug manufacturer Biofarm in a deal valued at about EUR257 million, says that Romania is one of its strategic...
ASF Greenlights Biofarm’s Takeover By Poland’s Polpharma
Romania’s Financial Supervisory Authority (ASF) has officially approved the tender offer through which the Polish group Polpharma intends to acquire the whole of pharmaceutical manufacturer...
Poland’s Zakłady Farmaceutyczne Polpharma Seeks To Buy Biofarma
Pharmaceutical company Biofarm (BIO.RO) is to become subject to a voluntary tender offer (VTO) from Zakłady Farmaceutyczne Polpharma S.A, a Polish pharmaceutical producer. The announcement c...
Biofarm Net Profit Edges Up to RON32.5M in Q1/2026
Drug and supplement producer Biofarm ended the first quarter of 2026 with RON32.5 million net profit, up 0.6% from Q1/2025, despite smaller sales revenues and rising operational expenses.
Biofarm Seeks To Pay Out RON41M Worth Of Dividends, Almost Half Of Its 2025 Net Profit
The Board of Directors of drug manufacturer Biofarm (stock symbol: BIO) has convened the general meeting of shareholders on April 28 to vote on distributing dividends in the amount of RON41....
Biofarm Seeks Development Opportunities
Drug manufacturer Biofarm Bucuresti wants to identify strategic opportunities supporting the company’s development plans, considering organic investments among others, but also identifying s...
Biofarm 9M/2025 Turnover Up 14% YoY To RON263M
Drug manufacturer Biofarm (stock symbol: BIO) ended the first nine months of 2025 with a turnover of RON263.2 million, up 14% against the year-earlier period, and EBITDA climbed 16% to RON10...